Výsledky vyhledávání

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

Autor: J. Eremin, Wolfgang Eiermann, J. Appfelstaedt, Louis Mauriac, M. Dugan, J. Vinholes, Vladimir Semiglazov, Antonio Llombart-Cussac, S. Paepke, H. A. Chaudri-Ross, M. Lassus, Mieke Borgs, Matthew J. Ellis

Publikováno v: Annals of Oncology. 12:1527-1532

Background: A randomized, double-blind, multicenter study was conducted to compare the anti-tumor activity of letrozole vs. tamoxifen in postmenopausal women with ER and/or PgR positive primary untreated breast cancer. Patients and methods: Three hun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e3decaa6ab182dca32daf7d9d4753b7
https://doi.org/10.1023/a:1013128213451

Zobrazit plný text záznamu

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

Autor: Louis Mauriac, Dean B. Evans, Baljit Singh, Matthew J. Ellis, Carolyn Brady, Mieke Borgs, Andrew Coop, Erhard Quebe-Fehling, Fritz Jänicke, Margaret Dugan, William R. Miller, Antonio Llombert-Cussac

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(18)

PURPOSE: Expression of ErbB-1 and ErbB-2 (epidermal growth factor receptor and HER2/neu) in breast cancer may cause tamoxifen resistance, but not all studies concur. Additionally, the relationship between ErbB-1 and ErbB-2 expression and response to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca09c0dada4d165cd81061d67ec821f5
https://pubmed.ncbi.nlm.nih.gov/11559715

Zobrazit plný text záznamu

Correlation of Immunohistochemistry (IHC) and gene microarray analysis of breast biopsies from a preoperative endocrine therapy trial

Autor: D.B. Evans, Fritz Jänicke, Mieke Borgs, M. Polymeropoulos, C. Lavedan, Antonio Llombart-Cussac, William R. Miller, A. Coop, B. Singh, M. Dressman, Louis Mauriac

Publikováno v: European Journal of Cancer. 37:9-10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cf58f7befe919ebfebf1d395b5fa774
https://doi.org/10.1016/s0959-8049(01)80058-7

Zobrazit plný text záznamu

Letrozole (femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer

Autor: A. Coop, B. Sing, D.B. Evans, Antonio Llombart-Cussac, Mieke Borgs, C. Brady, E. Quebe-Fehling, M. Dugan, Matthew J. Ellis, Fritz Jänicke, William R. Miller

Publikováno v: European Journal of Cancer. 37:8

Background: The agonist effects of tamoxifen (TAM) may limit efficacy against some breast cancers but the extent to which these agonist effects occur is unknown. To address this issue, changes in estrogen-regulated gene expression were monitored duri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2d907e84d2bffc11a8cab9567311393
https://doi.org/10.1016/s0959-8049(01)80054-x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání